All who met referral criteria pre-disclosure were identified to have a RET (n=3) or SDHx variant (3 SDHB, 1 SDHD); three had a personal history of paragangliomas (2 SDHB, 1 SDHD) and four had a self-reported family history warranting referral — one with an SDHB variant who reported a first-degree relative with renal cell carcinoma before age 50 and three with RET variants who reported that a family member had been clinically identified to carry the variant prior to result disclosure. This evidence concerns the gene SDHB and paraganglioma.